Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytoplasmic dynein 2 intermediate chain 2 (DYNC2I2, also known as WDR34) is a non-catalytic accessory subunit of the cytoplasmic dynein-2 complex, which is a motor protein complex critical for retrograde intraflagellar transport (IFT)—the movement of protein and molecular cargoes from the tip to the base of cilia and flagella, essential for normal ciliogenesis and ciliary signaling. It belongs to the WD repeat protein family, facilitating multiprotein complex formation and interaction. The dynein-2 complex contains two heavy chains, each partnering with either WDR34 (DYNC2I2) or WDR60, forming a heterodimer needed for proper dynein-2 function and cilia assembly. DYNC2I2 is involved in maintaining the transition zone in cilia, and defects in this gene cause short-rib thoracic dysplasia 11 with or without polydactyly. It can also act as a modulator of inflammation by negatively regulating the NF-κB pathway through inhibition of MAP3K7-induced signaling[1][4][3][5]. No clinically approved drugs directly target DYNC2I2; it functions primarily in structural and transport roles and is not currently considered a direct therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytoplasmic dynein 2 intermediate chain 2 (DYNC2I2).